See every side of every news story
Get Started
SubscribeLogin
CPAC
Donald Trump
Basketball
Pope Francis
Baseball
Hamas
Elon Musk
Israel-Hamas Conflict
South America
Premier League
Javier Milei
Arsenal FC
Published • loading... • Updated

Cost-Effectiveness Study: Libtayo “More Favorable” Than Keytruda for First-Line Treatment of Advanced NSCLC

Summary by Managed Healthcare Executive
Study shows that Libtayo plus chemotherapy has lower cost and a larger effect on improving quality-adjusted life years than Keytruda plus chemotherapy as first-line treatment for patients with non-small cell lung cancer.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Managed Healthcare ExecutiveManaged Healthcare Executive

Cost-Effectiveness Study: Libtayo “More Favorable” Than Keytruda for First-Line Treatment of Advanced NSCLC

Study shows that Libtayo plus chemotherapy has lower cost and a larger effect on improving quality-adjusted life years than Keytruda plus chemotherapy as first-line treatment for patients with non-small cell lung cancer.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Managed Healthcare Executive broke the news in on Monday, February 17, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
For You
Search
BlindspotLocal